Balamapimod

CAS No. 863029-99-6

Balamapimod( MKI-833 | MKI833 )

Catalog No. M16245 CAS No. 863029-99-6

Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Balamapimod
  • Note
    Research use only, not for human use.
  • Brief Description
    Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
  • Description
    Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MKI-833 | MKI833
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    863029-99-6
  • Formula Weight
    574.144
  • Molecular Formula
    C30H32ClN7OS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#CC1=C(NC2=CC=C(SC3=NC=CN3C)C(Cl)=C2)C4=CC(OC)=C(N5CCC(N6CCCC6)CC5)C=C4N=C1
  • Chemical Name
    4-[[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]amino]-6-methoxy-7-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-quinolinecarbonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Xl-281

    Xl-281 (BMS-908662) is a BRAF inhibitor with anti-tumor activity for the study of colorectal cancer and melanoma.

  • ZINC72115182

    N-(3-(5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide is a novel selective inhibitor.

  • GSK2008607

    GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.